- False-positive results on mammographic screen are associated with elevated risk of screen-detected and interval breast cancers for 12 years.
- A second false-positive result is associated with even higher risk of screen-detected and interval breast cancers.
Why this matters
- Women with false-positive results may warrant more vigilant surveillance for breast cancer.
- Population-based study of cohorts (age, 50-69 years) from 3 countries (Denmark, Norway, and Spain) (n=1,149,467 baseline screenings).
- False-positive screen is recall for further assessment after an abnormal screen without confirmation of breast cancer diagnosis.
- Screen-detected breast cancer is diagnosis at further assessment of an abnormal screen.
- Interval breast cancer is diagnosis after a negative screen or false-positive screen before the next screening (2 years).
- Funding: None.
- Average follow-up for screen-detected cancers was 5.6 years; interval cancer was 6.3 years.
- A false-positive result (vs negative result) was associated with a 2-fold higher risk of screen-detected (HR, 2.04; 95% CI, 1.93-2.16) and interval breast cancer (HR, 2.18; 95% CI, 2.02-2.34).
- Second false-positive result (vs negative results) was associated with a 4-fold higher risk of screen-detected (HR, 4.71; 95% CI, 3.81-5.83) and interval breast cancer (HR, 4.22; 95% CI, 3.27-5.46).
- Breast cancer risk after the first or second false-positive was elevated for 12 years after baseline screen.
- Observational design.